Abstract
Hallucinogen persisting perception disorder (HPPD) is rarely encountered in clinical settings. It is described as a re-experiencing of some perceptual distortions induced while intoxicated and suggested to subsequently cause functional impairment or anxiety. Two forms exist: Type 1, which are brief “flashbacks,” and Type 2 claimed to be chronic, waxing, and waning over months to years. A review of HPPD is presented. In addition, data from a comprehensive survey of 20 subjects reporting Type-2 HPPD-like symptoms are presented and evaluated. Dissociative Symptoms are consistently associated with HPPD. Results of the survey suggest that HPPD is in most cases due to a subtle over-activation of predominantly neural visual pathways that worsens anxiety after ingestion of arousal-altering drugs, including non-hallucinogenic substances. Individual or family histories of anxiety and pre-drug use complaints of tinnitus, eye floaters, and concentration problems may predict vulnerability for HPPD. Future research should take a broader outlook as many perceptual symptoms reported were not first experienced while intoxicated and are partially associated with pre-existing psychiatric comorbidity.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Abraham HD (1982) A chronic impairment of colour vision in users of LSD. Brit J Psychiatry 140:518–520
Abraham HD (1983) Visual phenomenology of the LSD flashback. Arch Gen Psychiatry 40:884–889
Abraham HD (1984) LSD flashbacks (In reply). Arch Gen Psychiatry 41:632–633
Abraham HD, Aldridge A (1993) Adverse consequences of LSD. Addiction 88:327–334
Abraham HD, Duffy FH (1996) Stable qEEG differences in post-LSD visual disorder by split half analysis: evidence for disinhibition. Psychiatry Res 67:173–187
Abraham HD, Duffy FH (2001) EEG coherence in post-LSD visual hallucinations. Psychiatry Res 107:151–163
Abraham HD, Mamen A (1996) LSD-like panic from risperidone in post-LSD visual disorder. J Clin Psychopharmacol 16:238–241
Abraham HD, Aldridge AM, Gogia P (1996) The psychopharmacology of hallucinogens. Neuropsychopharmacology 14:286–298
Alarcon RD, Dickinson WA, Dohn HH (1982) Flashback phenomena, clinical and diagnostic dilemmas. J Nerv Ment Dis 170:217–223
Aldurra G, Crayton JW (2001) Improvement of hallucinogen persisting perception disorder by treatment with a combination of fluoxetine and olanzapine: case report. J Clin Psychopharmacol 21:343–344
American Psychiatric Association (2013) Diagnostic and statistical manual of mental diseases (DSM-V), 5th edn. American Psychiatric Association Press, Washington, DC
Baggott MJ, Coyle JR, Erowid E, Erowid F, Robertson LC (2011) Abnormal visual experiences in individuals with histories of hallucinogen use, a web-based questionnaire. Drug Alcohol Depend 114:61–67
Bernstein-Carlson EB, Putnam FW (1986) Development, reliability, and validity of a dissociation scale. J Nerv Ment Dis 174:727–735
Brimblecombe RW, Pinder R (1975) Hallucinogenic agents. Wright-Scientechnica, Bristol
Carlson EB, Putnam FW (1993) An update on the dissociative experiences scale. Dissociation 6:16–27
Cohen S (1960) LSD, side effects and complications. J Nerv Ment Dis 130:30–40
Cohen S (1977) Flashbacks. Drug Abuse Alcohol Newslett 6:1–4
Dixon JC (1963) Depersonalization phenomena in a sample of college students. Br J Psychiatry 109:371–375
Ellis H (1898) Mescal: a new artificial paradise. Contemp Rev 73: 130–141 (reprinted in The Smithsonian Institution Annual Report 1898, 537–548)
Fischer R (1971) The “flashback”: arousal-statebound recall of experience. J Psychedelic Drugs 3:31–39
Fischer R (1976) On the remembrance of things present: the state-bound and stage-bound nature of consciousness. Man-Environ Syst 6:131–136
Goldman S, Galarneau D, Friedman R (2007) New onset LSD flashback syndrome triggered by the initiation of SSRIs. Ochsner J 7:37–39
Grinspoon L, Bakalar J (1997) Psychedelics reconsidered, 3rd edn. The Lindesmith Center, New York
Halpern JH, Jr Pope HG (2003) Hallucinogen persisting perception disorder, what do we know after 50 years? Drug Alcohol Depen 69:109–119
Hasse HE, Waldmann H (1971) “Flashback”, Spontane psychotische Episoden als Folgeerscheinung des Phantasticagebrauchs Jugendlicher. Arch Psychiat Nervenkr 214:399–439
Heaton RK, Victor RG (1976) Personality characteristics associated with psychedelic flashbacks in natural and experimental settings. J Abnorm Psychol 85:83–90
Hermle L, Kovar KA, Hewer W, Ruchsow M (2008) Halluzinogen-induzierte psychische Störungen. Fortschr Neurol Psychiatr 76:334–342
Hermle L, Ruchsow M, Täschner KL (2015) Halluzinogen-induzierte Persistierende Wahrnehmungsstörung (HPPD) und Flashback-Phänomene-Differenzialdiagnose und Erklärungsmodelle. Fortschr Neurol Psychiatr 83:506–515
Holland D, Passie T (2011) Flashback-Phaenomene als Nachwirkung von Halluzinogeneinnahme VWB-Verlag, Berlin
Holsten F (1976) Flashbacks, clinical and social significance 1.5–4 years after the first admission. Tidsskr f d norske Lægefor 96:876–878
Horowitz MJ (1969) Flashbacks: recurrent intrusive images after the use of LSD. Am J Psychiatry 126:565–569
Horton JC, Trobe JD (1999) Akinetopsia from nefazodone toxicity. Am J Ophthalmol 128:530–531
Hughes MS, Lessell S (1990) Trazodone-induced palinopsia. Arch Ophthalmol 108:399–400
Ihde-Scholl T, Jefferson JW (2001) Mitrazapine-associated palinopsia. J Clin Psychiatry 62:373
Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE (2013) Monitoring the future national survey results on drug use, 1975–2012. In: Volume II: college students and adults ages 19–50. Institute for Social Research, The University of Michigan, Ann Arbor
Kokoszka A (1992–1993) Occurrence of altered states of consciousness among students, profoundly and superficially altered states in wakefulness. Imagin Cogn Pers 12:231–247
Kokoszka H (1993) Flashbacks and schizophrenia. Irish J Psychol Med 10:37–39
Kraus RP (1996) Visual “trails” with nefazodone treatment. Am J Psychiatry 153:365–366
Lerner AG, Gelkopf M, Oyffe I, Finkel B, Katz S, Sigal M, Weizman A (2000) LSD-induced hallucinogen persisting perception disorder treatment with clonidine, an open pilot study. Int Clin Psychopharmacol 15:35–37
Lerner AG, Shufman E, Kodesh A, Kretzmer G, Sigal M (2002) LSD-induced Hallucinogen Persisting perception disorder with depressive features treated with reboxetine, case report. Is J Psychiatry Relat Sci 39:100–103
Malleson N (1971) Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Brit J Psychiatry 118:229–230
Markel H, Lee A, Holmes RD, Domino EF (1994) LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents. L Ped 125:817–819
Matefy RE, Hayes C, Hirsch J (1978) Psychedelic drug flashbacks, subjective reports and biographical data. Addict Behav 3:165–178
Matefy RE, Hayes C, Hirsch J (1979) Psychedelic drug flashbacks, attentional deficits? J Abnorm Psychol 88:212–225
Mayer-Gross W (1931) Über Synästhesien im Meskalinrausch. In: Anschütz G (Ed) Farbe-Ton-Forschungen Bd. III, pp 266–277. Hamburg Psychologisch-ästhetische Forschungsgesellschaft, Hamburg
McGlothlin H, Arnold D (1971) LSD revisited: a ten-year follow-up of medical LSD use. Arch Gen Psychiatry 24:35–49
Morehead DB (1997) Exacerbation of hallucinogen-persisting perception disorder with risperidone. J Clin Psychopharmacol 17:327–328
Naditch MP (1974) Acute adverse reactions to psychoactive drugs, drug usage, and psychopathology. J Psychoactive Drugs 22:305–311
Naditch MP, Fenwick S (1977) LSD flashbacks and ego functioning. J Abnormal Psychol 86:352–359
Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131–181
Parish E (1894) Über die Trugwahrnehmungen mit besonderer Berücksichtigung der internationalen Enquete über Wachhalluzinationen bei Gesunden. Schr Ges psychol Forsch 7(8):1–154
Passie T (1997) Psycholytic and psychedelic therapy Research: A complete international bibliography. Laurentius Publishers, Hannover
Passie T, Halpern JH (2014) The pharmacology of hallucinogens (Chapter 14). In: Ries RK, Fiellin DA (eds) Principles of addiction medicine, 5th edn. Lippincott Williams & Wilkins, NY
Passie T, Schneider U, Borsutzky M, Breyer R, Emrich HM, Bandelow B, Schmid-Ott G (2013) Impaired perceptual processing and conceptual cognition in patients with anxiety disorders: a pilot study with the binocular depth inversion paradigm. Psychol Health Med 18:363–374
Sandison RA, Whitelaw JD (1957) Further studies in the therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci 103:332–342
Shor RE (1960) The frequency of naturally occurring “hypnotic-like” experiences in the normal college population. Int J Clin Exp Hypn 8:151–156
Siegel RK, Jarvik ME (1975) Drug-induced hallucinations in animals and man. In: Siegel RK, West LJ (eds) Hallucinations: behavior, experience, and theory. Wiley, New York, pp 81–162
Stanton MD, Bardoni A (1972) Drug flashbacks, reported frequency in a military population. Am J Psychiatry 129:751–755
Strassman RJ (1984) Adverse reactions to psychedelic drugs, a review of the literature. J Nerv Ment Dis 172:577–595
Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25:1434–1452
Substance Abuse and Mental Health Services Administration (SAMHSA) (2011) Results from the 2010 national survey on drug use and health: summary of national findings. Substance Abuse and Mental Health Services Administration, Rockville
Wolfradt U, Oubaid V, Straube ER, Bischoff N, Mischo J (1999) Thinking styles, schizotypal traits and anomalous experiences. Pers Indiv Differ 27:821–830
World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders. World Health Organization, Geneva
Young CR (1997) Sertraline treatment of hallucinogen persisting perception disorder. J Clin Psychiatry 58:85
Acknowledgments
The authors thank Vicka Corey, Ph.D. for numerous helpful comments and suggestions to an earlier draft of the manuscript.
Conflict of interest:
The authors declare that there is no conflict of interest.
Funding:
Supported in part by an unrestricted grant by the HPPD Foundation (www.hppdfoundation.org).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Halpern, J.H., Lerner, A.G., Passie, T. (2016). A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD. In: Halberstadt, A.L., Vollenweider, F.X., Nichols, D.E. (eds) Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences, vol 36. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7854_2016_457
Download citation
DOI: https://doi.org/10.1007/7854_2016_457
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-55878-2
Online ISBN: 978-3-662-55880-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)